Brexpiprazole in Patients With Acute Schizophrenia

Model scores of the 29,894 trials active now.

Model score 12% for any early termination, 4% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 12% of the time (422 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2014-12-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 18.4% (raises risk) · Sponsor's track record
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: acutethe patientdiagnosispatient hasmay apply
  Phrases that lowered it: visitand safetyefficacy andtrsafety of
• Phase: 3 (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Disease area, neurology: No (lowers risk) · Disease area
• Number of arms: 3 (lowers risk) · Design
• Drug's FAERS reports in the prior 12 months: 11408 (lowers risk) · Drug's FDA history
• Sponsor's past trials: 49 (lowers risk) · Sponsor's track record
• Drug's FAERS reports before start: 58007 (lowers risk) · Drug's FDA history
• Maximum age: 65 (raises risk) · Who can join
• Has a data monitoring committee: No (lowers risk) · Design
• Drug's FAERS reports with a death: 11.0% (lowers risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 14 (lowers risk) · Sponsor's track record
• Responsible party: sponsor (lowers risk) · Design
• Disease area, psychiatry: Yes (raises risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Brexpiprazole in Patients With Schizophrenia NCT01810783 · started 2013 · scored riskier than 74% of active trials completed
• Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia NCT01668797 · started 2012 · scored riskier than 23% of active trials completed
• A Long-term Administration Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia NCT05326347 · started 2022 · scored riskier than 20% of active trials completed
• Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia NCT02013622 · started 2013 · scored riskier than 14% of active trials completed
• Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia NCT02054702 · started 2014 · scored riskier than 12% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.